Retatrutide New Zealand
Complete Research Guide 2026
Phase 3 TRIUMPH-4 data confirmed up to 28.7% average body weight reduction at 68 weeks — the strongest number ever reported in a major obesity trial. Phase 2 already showed 24.2% at 48 weeks. Here’s what the data actually says, and what New Zealand researchers need to know going into 2026.
Retatrutide remains investigational in New Zealand.
Retatrutide is not currently an approved consumer medicine in New Zealand. This guide covers the clinical data, mechanism, Medsafe context, fake-product risks, and COA verification issues NZ readers should understand before trusting online claims.
Read 2026 Status Guide →If you’ve landed here, you probably already know the broad story. The Phase 2 numbers were unusually strong, and when Phase 3 TRIUMPH-4 results landed in December 2025, it was clear Retatrutide wasn’t just another GLP compound. This guide gives a complete, New Zealand-focused overview of what the trial data actually shows — without the hype, without the overcomplicated clinical language.
2026 NZ status, Medsafe context and online-claim risk
Quick answer: retatrutide remains investigational and is not currently an approved consumer medicine in New Zealand. NZReta treats this page as a research and verification guide — not a buying guide, prescribing guide, dosing guide or supplier recommendation page.
For the full regulatory and safety context, read the Retatrutide NZ 2026 status guide. For specific legal context, see is retatrutide legal in New Zealand?. For product-risk checks, use the fake retatrutide and COA red flags guide.
What people call it — and what it actually is
You’ll see a few names used interchangeably: Retatrutide, Reta, and LY3437943. They all refer to the same compound. LY3437943 is Eli Lilly’s internal development code — most people in research circles just call it Reta.
Retatrutide is a synthetic peptide developed by Eli Lilly. It entered clinical trials in 2021 and became widely known after Phase 2 results were published in the New England Journal of Medicine in 2023. It sits in the same broad category as Ozempic (Semaglutide) and Tirzepatide, but works differently because it targets three receptor pathways simultaneously rather than one or two. That distinction is what makes the trial data so striking — and why it’s drawing sustained attention from researchers in New Zealand and globally.
Understanding what Retatrutide actually is also helps cut through a noisy market. The cleaner your grip on the mechanism and the published data, the easier it becomes to evaluate sources making claims about it.
How it works — the triple agonist explained simply
Compounds in this class work by activating receptor pathways involved in appetite regulation, glucose metabolism, and energy expenditure. The reason Retatrutide stands out mechanistically is that it doesn’t just target one pathway like Ozempic or two like Tirzepatide — it targets three simultaneously. For the deeper breakdown, read the full GLP-1 mechanism of action guide.
Three pathways, three complementary effects. The GLP-1 story was compelling. GLP-1 plus GIP was stronger. Adding glucagon appears to push the outcome further again — and the TRIUMPH trial program exists to validate that at scale.
What the trial data actually showed
Phase 1
Standard safety, tolerability, and pharmacokinetics work across different dose levels in healthy volunteers. It established the dose range and PK profile needed to design Phase 2, and cleared the way for the larger study without drama.
Phase 2 — the data that changed everything
Published in the New England Journal of Medicine, the Phase 2 trial enrolled 338 participants across six weekly dose groups over 48 weeks. The higher dose groups produced numbers that immediately exceeded anything previously seen in this compound class.
| Dose (weekly) | Mean body weight reduction | General takeaway |
|---|---|---|
| 1mg | ~8.7% | Clear effect over placebo |
| 2mg | ~12.9% | Meaningful improvement |
| 4mg | ~17.3% | Entering top-tier territory |
| 8mg | ~22.8% | Very strong outcome |
| 12mg | ~24.2% | Highest Phase 2 result — 48 weeks |
The dose-response relationship was consistent throughout: higher dose, stronger effect. The trial also reported improvements in metabolic markers beyond body weight — lipid profiles, blood pressure, and inflammatory markers — which broadened the conversation significantly beyond pure weight loss endpoints.
Retatrutide didn’t just look like “another GLP.” The Phase 2 data made clear that the extra glucagon pathway was contributing something materially different from what dual-agonist compounds had produced.
Phase 3 — the TRIUMPH program
The TRIUMPH program is Eli Lilly’s Phase 3 global registrational development program for Retatrutide. It launched in 2023 and has enrolled more than 5,800 participants across four major trials evaluating obesity, obstructive sleep apnea, knee osteoarthritis, and cardiovascular outcomes. Seven Phase 3 readouts are expected throughout 2026.
The first completed readout — TRIUMPH-4, focused on participants with obesity and knee osteoarthritis — was published in December 2025. It confirmed that the Phase 2 numbers weren’t anomalous, and extended the data into a longer 68-week timeframe with a different population.
Both the 9mg and 12mg doses met all primary and key secondary endpoints. Beyond the weight loss headline, TRIUMPH-4 reported a 75.8% average reduction in knee pain scores (WOMAC), meaningful improvements in physical function, cardiovascular risk marker reductions including non-HDL cholesterol and triglycerides, and a 14mmHg drop in systolic blood pressure at the 12mg dose. More than one in eight participants on the 9mg dose were completely free of knee pain by the end of the trial.
| Trial | Phase | Dose | Duration | Mean weight reduction |
|---|---|---|---|---|
| Phase 2 (NEJM) | P2 | 12mg | 48 wk | ~24.2% |
| TRIUMPH-4 | P3 | 9mg | 68 wk | ~26.4% |
| TRIUMPH-4 | P3 | 12mg | 68 wk | ~28.7% |
One new signal that emerged in TRIUMPH-4 was dysesthesia — an abnormal sense of touch — observed in 8.8% to 20.9% of participants on the higher doses. This was not reported in Phase 2 and is being watched closely across the remaining readouts. Gastrointestinal side effects (nausea, vomiting, diarrhea) followed the pattern seen in Phase 2 and were generally consistent with the broader GLP class. Discontinuation rates ran at 12.2–18.2% in the active arms versus 4% in placebo, with some attributed to perceived excessive weight loss in lower-BMI participants.
How Retatrutide compares with Ozempic and Tirzepatide
These are the comparisons most people are running when they search. A clean side-by-side, based on the best available trial data — keeping in mind that no published head-to-head Phase 3 trial exists between these three compounds.
For the full individual breakdowns, read Retatrutide vs Semaglutide and Retatrutide vs Tirzepatide.
Retatrutide vs Ozempic (Semaglutide)
Ozempic — and its weight-focused higher-dose version, Wegovy — both use Semaglutide, a GLP-1 receptor agonist working through a single pathway. It was a significant step forward when it launched, and still represents the dominant clinical reference point for this class. But the GLP-1-only ceiling shows clearly in the data: Semaglutide’s best Phase 3 numbers come in around 15–17% body weight reduction at comparable timepoints. Retatrutide’s Phase 2 results at 24.2% (48 weeks) and Phase 3 at 28.7% (68 weeks) reflect what GIP and glucagon agonism add on top of that GLP-1 base.
Retatrutide vs Tirzepatide (Mounjaro)
This is the closer and more interesting comparison, because Tirzepatide — sold as Mounjaro for diabetes and Zepbound for weight — already moved beyond GLP-1 with its dual GLP-1/GIP mechanism. Tirzepatide’s best Phase 3 results came in around 22.5% at comparable timepoints, which was a meaningful jump over Ozempic. Retatrutide’s Phase 3 at 28.7% appears to extend that line further — the working hypothesis being that glucagon agonism drives additional energy expenditure that neither GLP-1 nor GIP can reach alone. The data is directionally consistent with that theory, though full head-to-head Phase 3 data hasn’t been published.
| Compound | Receptor targets | Best trial result | NZ status (2026) |
|---|---|---|---|
| Ozempic / Wegovy Semaglutide | GLP-1 | ~17% 72wk, STEP trials | Ozempic approved; Wegovy pending |
| Mounjaro / Zepbound Tirzepatide | GLP-1 + GIP | ~22.5% 72wk, SURMOUNT | Mounjaro approved NZ; Zepbound not yet |
| Retatrutide LY3437943 | GLP-1 + GIP + Glucagon | ~28.7% 68wk, TRIUMPH-4 | Investigational — FDA submission expected 2026 |
Trial populations, endpoints, and timepoints differ — these aren’t apples-to-apples comparisons. But the directional signal is consistent across all three, and it aligns with the mechanistic story: each additional receptor pathway appears to meaningfully raise the ceiling.
What people in New Zealand are actually trying to figure out
Most New Zealand searches around Retatrutide aren’t just about the science. They’re about whether what they’re looking at is real — and whether they can actually evaluate the difference between a credible source and a well-dressed one. The research peptide market in NZ has grown alongside the GLP-1 conversation, and the quality signal-to-noise ratio isn’t great.
- What Retatrutide actually is and how it differs from Ozempic and Tirzepatide mechanistically
- What Phase 2 and Phase 3 TRIUMPH data actually showed — not a summary version
- How to assess quality markers like lot references, third-party testing, and COAs
- Which signals make a source genuinely credible versus just well-designed
- Whether the compound they’re looking at has traceable, verifiable batch documentation
The science answers are increasingly accessible. The harder problem is the quality question — and that’s where most researchers in NZ end up making decisions based on branding rather than documentation. For the wider content hub, use the complete NZ Retatrutide guides page.
For availability and buyer-intent context, use the updated where to buy retatrutide NZ availability guide. That page now focuses on legal status, Medsafe context, fake-product risks, and COA limitations rather than supplier recommendations.
Why verification matters more than hype
The problem with any high-attention research compound is that marketing language spreads faster than proof. Anyone can write clean copy about purity and potency. Very few suppliers can back it with consistent batch-level documentation, traceable COAs, and independently verified test results.
In New Zealand’s research peptide market, the gap between what’s claimed and what’s documented tends to be wide. The most reliable quality signal isn’t a product page — it’s whether a supplier can produce a lot-specific Certificate of Analysis from a named third-party laboratory, with a batch number that can be cross-referenced back to an actual test report.
What to look for in a COA: A meaningful Certificate of Analysis includes the specific lot or batch number, the testing laboratory name (third-party, not in-house), purity percentage confirmed by HPLC (typically ≥98%), the test date, and a report reference that can be independently verified. A COA without a traceable batch number and named laboratory is essentially decorative — it signals nothing about the actual compound in the vial.
When you’re evaluating online retatrutide claims in New Zealand specifically, the clearest quality signals are batch-level traceability, HPLC purity confirmation, identity confirmation, and documentation consistency. Even then, COAs are only evidence about a tested batch — they are not Medsafe approval, sterility assurance, prescribing advice, or proof that a product is safe for human use.
Frequently asked questions about Retatrutide
As of 2026, Retatrutide is not commercially approved in New Zealand. It remains an investigational compound undergoing Phase 3 clinical trials under Eli Lilly’s TRIUMPH program. FDA approval is projected in 2026 or 2027, with Medsafe approval for New Zealand typically following with an additional 12–24 month delay depending on the application pathway.
NZReta does not list, endorse, supply, prescribe, or recommend retatrutide suppliers. Readers should treat online availability claims carefully, check Medsafe context, and review batch-specific documentation before trusting any product claim.
Yes. LY3437943 is Eli Lilly’s internal development code for Retatrutide. Both names refer to the same compound — a once-weekly injectable triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Most people in research communities just call it Reta.
Ozempic and Wegovy both use Semaglutide, which works through the GLP-1 receptor only — a single pathway. Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The addition of GIP amplifies glucose and insulin-related effects, while glucagon receptor activity drives additional energy expenditure and fat metabolism that GLP-1 alone doesn’t reach.
In practical terms: Semaglutide’s best Phase 3 data shows approximately 15–17% body weight reduction at comparable timepoints. Retatrutide’s Phase 2 showed 24.2% at 48 weeks, and Phase 3 TRIUMPH-4 showed 28.7% at 68 weeks.
TRIUMPH-4 was Lilly’s first Phase 3 readout for Retatrutide, announced in December 2025. It enrolled 445 participants with obesity and knee osteoarthritis over 68 weeks. The 12mg dose group lost an average of 28.7% of body weight — roughly 71.2 lbs. Both the 9mg and 12mg doses met all primary and key secondary endpoints.
Beyond weight loss, the trial reported a 75.8% reduction in knee pain scores (WOMAC), significant improvements in physical function, and reductions in cardiovascular risk markers including non-HDL cholesterol, triglycerides, and C-reactive protein. Systolic blood pressure dropped by an average of 14mmHg at the highest dose. More than one in eight participants on the 9mg dose were completely free of knee pain by the end of the trial.
A new safety signal — dysesthesia (an abnormal sense of touch) — was observed in 8.8–20.9% of participants at higher doses, which was not reported in Phase 2. Seven additional Phase 3 readouts are expected throughout 2026.
The most commonly reported side effects across clinical trials are gastrointestinal: nausea (up to 43% in Phase 3), vomiting (21%), and diarrhea (33%). These occur primarily during dose escalation and are generally mild to moderate. The standard Retatrutide dosing protocol starts at 2mg weekly and increases in steps every four weeks — a pace designed to improve tolerability.
In Phase 3, a new signal called dysesthesia — an abnormal sensation of touch — appeared in 8.8% to 20.9% of participants on the 9mg and 12mg doses respectively. This was not observed in Phase 2 and is being monitored closely across remaining TRIUMPH readouts. Discontinuation rates in TRIUMPH-4 were 12.2–18.2% in the active arms vs 4% in placebo.
Tirzepatide (Mounjaro for diabetes, Zepbound for weight) targets two receptors — GLP-1 and GIP. Retatrutide adds a third: glucagon. In Phase 3, Tirzepatide’s best results showed approximately 22.5% body weight reduction at comparable timepoints. Retatrutide’s TRIUMPH-4 showed 28.7% at 68 weeks — a meaningful gap, even accounting for population and timepoint differences.
The working hypothesis is that glucagon receptor agonism drives additional energy expenditure that GLP-1/GIP cannot replicate alone. There is no published head-to-head Phase 3 trial between the two compounds, so cross-trial data comparisons carry limitations. The directional story from the mechanism and trial data is consistent, though.
FDA approval is projected in 2026 or 2027. Seven additional Phase 3 readouts from the TRIUMPH program are expected throughout 2026, which will inform Lilly’s NDA submission timing and the indications sought. Standard FDA review takes 10–12 months from submission.
New Zealand Medsafe approval would typically follow FDA clearance with an additional delay of 12–24 months. These are projections rather than confirmed timelines — clinical programs can encounter delays, and regulatory timelines vary.
A COA (Certificate of Analysis) is a document from a third-party laboratory that verifies the identity, purity, and concentration of a compound for a specific batch. For Retatrutide, a meaningful COA includes the batch or lot number, the testing laboratory name (third-party, not in-house), purity percentage confirmed by HPLC (typically ≥98%), the test date, and a report reference that can be independently traced.
In New Zealand’s research peptide market, COAs are commonly displayed but not always traceable. A COA without a specific batch number and named external laboratory tells you very little about what’s actually in the vial. Batch-level traceability — the ability to match a document to a specific lot — is the quality signal that actually matters.
Yes — the TRIUMPH Phase 3 program covers a wide range of indications: obesity and overweight with related complications, type 2 diabetes, knee osteoarthritis, obstructive sleep apnea, chronic low back pain, cardiovascular outcomes, and metabolic dysfunction-associated steatotic liver disease (MASLD).
TRIUMPH-4 — the knee osteoarthritis population — showed the weight loss outcomes above alongside substantial reductions in pain and improvements in physical function. Seven more Phase 3 readouts covering the other populations are expected in 2026, which will determine the full breadth of any regulatory submission.
Sources and further reading
This page is for informational and research discussion purposes only. It does not provide medical advice, diagnosis, treatment, dosing guidance, sourcing advice or therapeutic recommendations. Retatrutide (LY3437943) is an investigational compound and is not approved for consumer therapeutic use in New Zealand as of 2026.